When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy

Published:2018-02-15 Issue:4 Volume:34 Page:e2981
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Avogaro Angelo¹,Delgado Elías²³⁴^ORCID,Lingvay Ildiko⁵

Affiliation:

1. Department of Internal Medicine, Unit of Metabolic Disease; University of Padova; Padova Italy

2. Department of Endocrinology and Nutrition; University of Oviedo; Oviedo Spain

3. Endocrinology and Nutrition Department; Hospital Universitario Central de Asturias; Oviedo Spain

4. Metabolism Unit; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA); Asturias Spain

5. Internal Medicine/Endocrinology and Clinical Sciences; University of Texas Southwestern Medical Center; Dallas TX USA

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference141 articles.

1. Scottish Diabetes Survey Monitoring Group Scottish diabetes survey 2015 2015 diabetesinscotland.org.uk

2. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors;Daousi;Postgrad Med J,2006

3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group;UK Prospective Diabetes Study (UKPDS) Group;Lancet,1998

4. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review;Colosia;Diabetes Metab Syndr Obes,2013

5. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors;Kabakov;J Cardiometab Syndr,2006

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach;Diabetologia;2024-06-05

2. Antidiabetic effectiveness of Phyllanthus niruri bioactive compounds via targeting DPP-IV;Natural Product Research;2024-04-09

3. Progress in the treatment of diabetic cardiomyopathy, a systematic review;Pharmacology Research & Perspectives;2024-02-26

4. Safety and effectiveness of SGLT2-inhibitors in people with type 2 diabetes over 70: UK population-based study using an Instrumental Variable approach;2024-01-04

5. Type 2 diabetes mellitus: Novel targets and multitarget-directed phytotherapy;Antidiabetic Medicinal Plants;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3